Health
Dyadic C1 protein expression platform explored in fight against COVID-19 – Medical Plastics News
Dyadic International, Inc. has announced results which further support record expression levels of the SARS-CoV-2 Receptor Binding Domain (RBD) antigen produced…
Dyadic International, Inc. has announced results which further support record expression levels of the SARS-CoV-2 Receptor Binding Domain (RBD) antigen produced from Dyadics industrially proven proprietary and patented hyper-productive C1 gene expression platform.
The RBD was produced at three grams per liter (3 g/l) in only five days.
Dyadics C1 Rapid Recombinant Protein Manufacturing Platform can manufacture monoclonal antibodies (mAbs) more efficiently and faster than currently existing C…
-
Noosa News21 hours agoPill checking to resume in Queensland months after government axed funding
-
Noosa News19 hours agoQueensland girl Millie’s fight for life after magnets tore through her bowel
-
Business24 hours agoWhy Lynas, Mesoblast, PEXA, and Sayona Mining shares are tumbling today
-
Business24 hours agoBrokers name 3 ASX shares to buy today 29 August 2025